Sunday 20 January 2019
Home      All news      Contact us     
Reuters - 9 days ago

REFILE-Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

Related news

Latest News
Hashtags:   

REFILE

 | 

Lilly

 | 

cancer

 | 

deals

 | 

therapy

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Sources